Navigation Links
PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day

BOSTON, May 30, 2012 /PRNewswire/ -- Today, in conjunction with its Investor Day being held tomorrow in New York City, PAREXEL International Corporation (Nasdaq: PRXL) announced forward-looking earnings expectations for the fourth quarter of Fiscal Year 2012 (ending June 30, 2012), for Fiscal Year 2012, and for Fiscal Year 2013. 

The Company reconfirmed its guidance for the fourth quarter of Fiscal Year 2012 and for all of Fiscal Year 2012, as issued in a press release dated April 30, 2012.  To reiterate, for the fourth quarter of Fiscal Year 2012, the Company anticipates reporting consolidated service revenue in the range of $376.0 to $381.0 million, and diluted earnings per share as reported under Generally Accepted Accounting Principles (GAAP) of $0.28 to $0.30.  For Fiscal Year 2012 (ending June 30, 2012), the Company continues to expect consolidated service revenue to be in the range of $1.380 to $1.385 billion, GAAP earnings per diluted share to be $1.03 to $1.05, and adjusted earnings per diluted share to be in the range of $1.04 to $1.06.   Adjusted numbers exclude the impact of restructuring-related charges and certain Q3 FY12 tax benefits, as previously described in the April 30th press release. 

The Company is providing guidance estimates for Fiscal Year 2013 for the first time, and anticipates reporting consolidated service revenue in the range of $1.625 to $1.655 billion, and GAAP earnings per diluted share of $1.31 to $1.47.

Those who wish to listen to the Company's Investor Day presentations and to view the accompanying slides should log onto the Company's website at and click on the PAREXEL Investor Day link under the "Upcoming Events" section of the Investors homepage at least 15 minutes prior to the event's broadcast which will start at 8:30 a.m. ET.  Users should follow the instructions provided to assure that the necessary audio applications are downloaded and installed.  In addition, an archived version of the event's presentations will be located in the Investor Relations section of PAREXEL's website.

About the Company

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 50 countries around the world, and has approximately 11,920 employees. For more information about PAREXEL International visit

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 as filed with the SEC on May 10, 2012, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.


James Winschel, Senior Vice President and Chief Financial Officer

Jill Baker, Corporate Vice President of Investor Relations


SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Chairman And CEO To Ring The Bell At The NASDAQ Stock Market Opening
2. Parexel Invites Public To Listen To Live Webcast Of Its Investor Day May 31, 2012
3. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
4. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
5. PAREXEL Announces Date of Third Quarter Fiscal Year 2012 Earnings Release and Conference Call
6. PAREXEL to Address New Regulatory Guidelines and Data Standards at DIA EuroMeeting
7. PAREXEL Global Survey Results Identify Top Concerns of Biopharma Industry in Achieving Commercial Success
8. PAREXEL International to Present at Barclays Capital Healthcare Conference
9. PAREXEL International to Present at Cowen Healthcare Conference and Raymond James Investors Conference
10. PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives
11. PAREXEL Expands Alliance Network to Support Early Phase Patient Studies, Establishes Collaboration With University Hospitals Bristol NHS Foundation Trust
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
(Date:11/25/2015)... issue of United States patent No. 9,192,509  entitled: " Methods and Apparatus ... AVACEN 100 dry heat therapy medical device and specific methods of use, referred to by the ... - ... ... ...
(Date:11/25/2015)... , November 25, 2015 ... Investors"), pursuant to which BioLight and the New Investors ... Ltd. subsidiary ("IOPtima") via a private placement. The financing ... its innovative IOPtimate™ system used in the treatment of ... pathway process for the IOPtimate™ system with the U.S. ...
Breaking Medicine Technology:
(Date:11/26/2015)... Cambridge, ON (PRWEB) , ... November 26, 2015 ... ... availability of a real-time eReferral system for diagnostic imaging in the Waterloo region. ... mammography, BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating their record books ... their 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the PRMA ... rebuild lives and it’s an honor to have served all of these women.” , ...
(Date:11/26/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact ... and reliability. , The new Q-Suite 6 platform is based on the latest Java ... into a specific piece of software for many key components of the suite. Much ...
(Date:11/25/2015)... Cokato, MN (PRWEB) , ... November 25, 2015 , ... ... Thanksgiving through Christmas Eve on several models of traditional and far-infrared saunas. ... . Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only ...
(Date:11/25/2015)... ... November 26, 2015 , ... ... (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public R&D ... Nairobi (UNON) for the opening of the 5th African Network for Drugs and ...
Breaking Medicine News(10 mins):